# US 2001/0034343 A1 · Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034343 A1
- Document ID: US20010034343A1
- Status: Published application
- Kind: A1
- Application number: 09/739,741
- Filed: 2000-12-18
- Published: 2001-10-25
- Earliest claimed: 1995-12-20
- Assignees: Aventis Pharmaceuticals Inc.
- Inventors: George D. Maynard; Tieu-Binh Le
- Web page: https://patentgrep.com/patent/US20010034343A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula 1 and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

## Claims

### Claim 1

A compound, including enantiomers, stereoisomers, rotomers and tautomers of said compound and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in the formula:
153
wherein
m is 2 or 3;
A is 1 or 2;
G is —C(O)—, —C(O)—CH2—, or —SO2—;
R30 is selected from the group consisting of:
—C5-C8 alkyl, —(CH2)pCF3, vinyl,
154
wherein
p is an integer from 1 to 4;
B is an integer from 1 to 4;
D is an integer from 1 to 4;
s is an integer from 1 to 4; and
R34 is C1-C4 alkyl;
R3, and R32 are the same or different and are independently selected from hydrogen or C1-C4 alkoxy; and
R33 is selected from the group consisting of:
hydrogen, C1-C4 alkoxy,
155
wherein
E is an integer from 2 to 4.

### Claim 2 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-(2-cyclopropyhnethoxyethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(2-methoxy-5-tetrazol-1-yl-phenyl)-methanone having the formula:
156
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 3 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-cyclopropylmethyl-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(2-methoxy-5-tetrazol-1-yl-phenyl)—methanone having the formula:
157
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 4 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-(2-(4-(1-(2-(5-methyl-tetrazol-1-yl)-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-methanone having the formula:
158
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 5 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-(2-(2-methoxy-ethoxy)ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(2-methoxy-5-tetrazol-1-yl-phenyl)-methanone having the formula:
159
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 6 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-(2-(4-(1-(2-methyl-thiazol-4-ylmethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-methanone having the formula:
160
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 7 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-phenyl-3-(2-(4-(1-(2-pyrazol-1-yl-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-pyrrolidin-1-yl)-methanone having the formula:
161
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 8 (depends on 1)

The compound as set forth in claim 1 which is methanesulfonic acid 3-(1-((R)-3-(2-(4-(1-(2-ethoxy-ethyl)-1H-berizoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-methanoyl)-4-methoxy-phenyl ester having the formula:
162
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 9 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(2-methoxy-5-(2-methoxy-ethoxy)-phenyl)-methanone having the formula:
163
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 10 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-(2-)4-(1-pentyl-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-methanone having the formula:
164
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 11 (depends on 1)

The compound as set forth in claim 1 which is 1-(3-(1-((R)-3-(2-(4-(1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)methanoyl)-4-methoxy-phenoxy)-propan-2-one having the formula:
165
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 12 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-phenyl-3-(2-(4-(1-(2,2,2-trifluoro-ethyl)-H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-pyrrolidin-1-yl)-methanone having the formula:
166
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 13 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-phenyl-3-(2-(4-(1-(4,4,4-trifluoro-butyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-pyrrolidin-1-yl)-methanone having the formula:
167
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 14 (depends on 1)

The compound as set forth in claim 1 which is 1-(2-methoxy-5-tetrazol-1-yl-phenyl)-1-((R)-3-phenyl-3-(2-(4-(1-vinyl-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl(-ethyl)-pyrrolidin-1-yl)-methanone having the formula:
168
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 15 (depends on 1)

The compound as set forth in claim 1 which is methanesulfonic acid 4-(1-((R)-3-(2-(4-(1-2(ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-methanoyl)-2,6-dimethoxy-phenyl ester hydrochloride having the formula:
169
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 16 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(2-methoxy-5-(3-methylsulfanyl-(1,2,4)triazol-4-yl)-phenyl)-methanone having the formula:
170
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 17 (depends on 1)

The compound as set forth in claim 1 which is 1-((R)-3-(2-(4-(1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-pyrrolidin-1-yl)-1-(5-(3-methanesulfonyl-(1,2,4)triazol-4-yl)-2-methoxy-phenyl)-methanone having the formula:
171
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 18 (depends on 1)

The compound as set forth in claim 1 which is 2-(4-(2-((R)-1-(2,5-dimethoxy-benzenesulfonyl)-3-phenyl-pyrrolidin-3-yl)-ethyl)-(1,4)dizaepan-1-yl)-1-(2-ethoxy-ethyl)-1H-benzoimidazole hydrochloride having the formula:
172
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 19 (depends on 1)

The compound as set forth in claim 1 which is 1-(3-(2-(4-(1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl)-(1,4)diazepan-1-yl)-ethyl)-3-phenyl-azetidin-1-yl)-2-(3,4,5-trimethoxy-phenyl)-ethanone hydrochloride having the formula:
173
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A method for treating allergic rhinitis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 22 (depends on 1)

A method for treating asthma in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 23 (depends on 1)

A method for treating emesis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 1)

A method for treating uieitis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 25 (depends on 1)

A method for treating allergic conjuctivitis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 26 (depends on 1)

A method for treating ophthalmic allergies in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 27 (depends on 1)

A method for treating inflammatory bowel disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 1.
